By Sarah A. JonesSource ABC News | December 19, 2017 11:25 a.m.
ESTIn the past few months, the Food and Drug Administration has approved the use of three new medical growth drugs, the first of which, an extract from the medicinal nutraceuroutics plant Dandelion, has cleared regulatory hurdles.
But it is the second new product that has been approved that has caught the FDA’s attention: a drug that treats the condition of mustache growth, also known as withering or warts.
The product, called Dandelions Growth Medicine, is an extract of the medicinal root dandelion.
Its main ingredient is a compound that has the same properties as those found in the bark of dandelions, but the drug does not make the dandelian root grow again.
The DEA has granted approval to Dandelitions Growth Medicine under the terms of a new, two-year study program, according to a document obtained by ABC News.
The study is the first for an FDA-approved drug that targets a disease-modifying drug that has a long history of approval in the United States.
The program, called the Innovative Drug Discovery Program, began in 2009 and is aimed at addressing new and emerging drugs that may be effective for a range of conditions, such as cancer, diabetes, cardiovascular disease, and other chronic diseases, according the agency.
The FDA is also examining two other new drugs that have been approved in the past three years: a treatment for hepatitis C that is designed to improve the liver’s immune response, and a new treatment for multiple sclerosis that targets the spinal cord.
Both drugs target a type of immune response called T-cell mediated inflammation.
T-cells, which play a role in protecting us from disease and repair damage, are often thought to be the cause of witherings, which are common in patients with diabetes.
But scientists say there are many other factors that could also play a part in withers.
The first major study of the two drugs, published in The New England Journal of Medicine, found that they increased the severity of withering in patients.
In addition, the drugs also increased the risk of dying from a type-2 diabetes, which is caused by the breakdown of a healthy immune system.
In a statement, the Drug Enforcement Administration (DEA) said it is reviewing all the drug applications for the drugs and will provide more information about their safety and effectiveness.
The agency said it will also examine other drug applications that the FDA has received to determine if there are any differences in safety or effectiveness between them.
The agency is also considering other applications for drugs that target immune response and immune cells.
In the meantime, the FDA said the agency is continuing to evaluate other possible new drugs for the same or similar conditions.